Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario

BACKGROUND: Pharmacogenetic (PGx) testing identifies pharmacotherapeutic risks to permit personalized therapy. Identifying the genetic profile of patients with acute coronary syndrome (ACS) who are considered for therapy with clopidogrel (P2Y(12) receptor blockers) and acetylsalicylic acid (ASA) con...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clinicoecon Outcomes Res
Main Authors: Bereza, Basil G, Coyle, Doug, So, Derek Y, Kadziola, Zbigniew, Wells, George, Grootendorst, Paul, Papadimitropoulos, Emmanuel A
Format: Artigo
Jezik:Inglês
Izdano: Dove 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7090184/
https://ncbi.nlm.nih.gov/pubmed/32256091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S234298
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki